Celularity

Celularity, headquartered in Florham Park, New Jersey, is a clinical and commercial stage biotechnology company leading the next evolution in cellular and regenerative medicine. The company's innovative approach harnesses the unique therapeutic potential locked within the postpartum placenta — nature's immunotherapy engine — to develop off-the-shelf allogeneic placenta-derived cellular therapies including mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells including CAR-T cells. Celularity targets serious unmet medical needs across age-related diseases, cancer, infectious diseases, and degenerative conditions. Celularity has more than 15 active and completed clinical trials and operates an approximately 150,000-square-foot cGMP-ready manufacturing facility in Florham Park, NJ.